BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 24078271)

  • 21. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
    Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
    Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas.
    Skrypets T; Novosad O; Pastushenko Y; Gorbach O; Kriachok I
    Klin Onkol; 2019; 32(6):436-444. PubMed ID: 31842562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical significance of survivin expression in peripheral T-cell lymphoma].
    Xiang XJ; He YJ; Li YH; Huang H; Xu F
    Ai Zheng; 2006 Jun; 25(6):758-61. PubMed ID: 16764776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification.
    Kim K; Kim WS; Jung CW; Im YH; Kang WK; Lee MH; Park CH; Ko YH; Ree HJ; Park K
    Eur J Cancer; 2002 Jan; 38(1):75-81. PubMed ID: 11750843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome?
    Pileri A; Pellegrini C; Agostinelli C; Grandi V; Patrizi A; Zinzani PL; Pimpinelli N
    Eur J Dermatol; 2017 Feb; 27(1):49-53. PubMed ID: 27873737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
    Akagi T; Takahashi N; Yamaguchi K; Ishizawa K; Murai K; Tajima K; Ikeda K; Kameoka Y; Kameoka J; Ito S; Kato Y; Noji H; Shichishima T; Itoh J; Ichinohasama R; Harigae H; Ishida Y; Sawada K
    J Clin Exp Hematop; 2011; 51(1):29-35. PubMed ID: 21628858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
    Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
    Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapies for peripheral T-cell lymphomas.
    Savage KJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():515-24. PubMed ID: 22160083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
    Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. THE ROLE OF RADIATION THERAPY IN THE TREATMENT OF PTCL-NOS.
    Kriachok I; Aleksyk O; Tytorenko I; Bushuieva M; Moroz Y
    Probl Radiac Med Radiobiol; 2023 Dec; 28():504-512. PubMed ID: 38155144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral T-cell lymphoma with gastrointestinal involvement and indolent T-lymphoproliferative disorders of the gastrointestinal tract.
    Kohri M; Tsukasaki K; Akuzawa Y; Tanae K; Takahashi N; Saeki T; Okamura D; Ishikawa M; Maeda T; Kawai N; Matsuda A; Arai E; Arai S; Asou N
    Leuk Res; 2020 Apr; 91():106336. PubMed ID: 32151888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.
    López-Guillermo A; Cid J; Salar A; López A; Montalbán C; Castrillo JM; González M; Ribera JM; Brunet S; García-Conde J; Fernández de Sevilla A; Bosch F; Montserrat E
    Ann Oncol; 1998 Aug; 9(8):849-55. PubMed ID: 9789607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
    Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
    Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
    Hapgood G; Latimer M; Lee ST; Kuss B; Lade S; Tobin JWD; Purtill D; Campbell BA; Prince HM; Hawkes EA; Shortt J; Radeski D
    Intern Med J; 2022 Oct; 52(10):1806-1817. PubMed ID: 34668281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.